Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer

Septerna (Nasdaq: SEPN) announced on January 8, 2026 the appointment of Mark A. Wilson as Chief Legal Officer.

Rhea-AI Summary

Septerna (Nasdaq: SEPN) announced on January 8, 2026 the appointment of Mark A. Wilson as Chief Legal Officer. Mr. Wilson brings more than 25 years of pharmaceutical and biotech legal experience in intellectual property, corporate legal, strategic collaborations and governance. He joins from Nektar Therapeutics where he served as Senior Vice President and Chief Legal Officer and led global patent strategy, major development and commercialization collaborations, and alternative financings. Mr. Wilson held prior roles from Patent Counsel to General Counsel and is a J.D. from Seton Hall and a B.S. in Pharmacy from Rutgers; he is registered with the U.S. Patent and Trademark Office and a member of the California Bar.

Positive

• Appoints a Chief Legal Officer with 25+ years pharma/biotech legal experience
• Brings proven leadership in global patent strategy from prior role at Nektar
• Experience leading development/commercialization collaborations and financings
• Has executive committee and cross‑functional leadership overseeing legal, HR, and IT

Negative

• None.

Argus Jan 9 session

-1.71% close to close Open Argus

Details

News Market Reaction – SEPN

On Jan 9, the first trading day after this news, SEPN closed 1.71% below the previous close.

Data tracked by StockTitan Argus for the Jan 9 session.

Key Figures

Industry experience: more than 25 years Current price: $26.41 Daily move: 3.77% +5 more

Industry experience

more than 25 years

Mark A. Wilson’s pharmaceutical and biotech legal career

Current price

$26.41

Pre-news trading level on announcement day

Daily move

3.77%

Price change over prior 24 hours

52-week high

$30.50

Upper end of recent trading range

52-week low

$4.17

Lower end of recent trading range

Market cap

$1,139,503,186

Equity value prior to this leadership news

20-day avg volume

262,259 shares

Liquidity benchmark for recent trading

Today’s volume

304,103 shares

Trading activity prior to the announcement

Historical Context

5 past events · Latest: Dec 17

5 events

1. Dec 17

   Conference appearance

   24h Move

   +1.2%

   Announced J.P. Morgan Healthcare Conference presentation and webcast access.

2. Nov 25

   Conference appearance

   24h Move

   -1.9%

   Disclosed Evercore Healthcare Conference participation and webcast details.

3. Nov 10

   Earnings and update

   24h Move

   -2.2%

   Reported profitable Q3 2025, strong cash balance, and pipeline progress.

4. Nov 03

   Investor conferences

   24h Move

   -2.7%

   Outlined participation in two November 2025 investor conference fireside chats.

5. Sep 29

   Board appointment

   24h Move

   +4.0%

   Added veteran biotech leader to board and created R&D Committee chair role.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

g protein-coupled receptor, gpcr, intellectual property, patent, +2 more

6 terms

g protein-coupled receptor medical

"a new era of G protein-coupled receptor (GPCR) drug discovery"

A G protein-coupled receptor is a protein on a cell’s surface that acts like an antenna: it detects signals such as hormones, neurotransmitters or drugs outside the cell and passes that message inside to change cell behavior. Investors care because roughly a third of marketed medicines act on these receptors, so a company’s success in targeting or modulating a specific receptor can determine the value of drug candidates, regulatory risk, and future revenue potential.

gpcr medical

"a new era of G protein-coupled receptor (GPCR) drug discovery"

G protein-coupled receptors (GPCRs) are a large family of proteins on cell surfaces that act like locks sensing chemical signals — when the right key binds, they trigger internal cell responses. They matter to investors because GPCRs are the target of many marketed drugs and experimental therapies; success or failure in developing a GPCR-targeting drug can change a company’s revenue prospects, clinical progress, and licensing value, much like winning control of a widely used distribution channel.

intellectual property technical

"experience across intellectual property, corporate legal, strategic collaborations"

Intellectual property are legal rights that protect creations of the mind—such as inventions, brand names, designs, software, or secret formulas—giving the owner control over who can use, copy or sell them. For investors, IP is like owning a blueprint or recipe: it can generate steady income through exclusive sales or licensing, boost a company’s competitive edge and valuation, and also create costs or risks if rights must be defended or challenged in court.

patent technical

"a patent law firm in Menlo Park, California, where he represented"

A patent is a government-granted right that gives an inventor exclusive control to make, use, sell or license a specific invention for a limited time, usually in exchange for publicly describing how it works. For investors it matters because a patent can act like a time-limited lock on a product or process — reducing competition, protecting future sales or licensing income, and often increasing a company’s value, while still being defeasible, time-bound and subject to legal challenge.

u.s. patent and trademark office regulatory

"He is registered to practice before the U.S. Patent and Trademark Office"

The U.S. Patent and Trademark Office is the federal agency that reviews and grants patents and registers trademarks, like a land office that issues official property deeds for inventions and brand names. For investors, its decisions matter because patents and trademarks can create legal protection and exclusive market rights that boost a company’s revenue potential, reduce competition, and change risk and valuation dynamics.

corporate governance financial

"strategic collaborations and corporate governance matters."

Corporate governance is the system of rules, roles and oversight that determines how a company is directed and controlled, including the responsibilities of its board, executives and shareholders. Like the steering wheel and map for a car trip, it shapes decisions, sets checks on power and defines who can hold leaders accountable; strong governance reduces risk, builds trust and helps investors judge whether a company is likely to protect capital and deliver reliable returns.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Mark A. Wilson as Chief Legal Officer. Mr. Wilson is an accomplished pharmaceutical and biotech executive with more than 25 years of experience across intellectual property, corporate legal, strategic collaborations and corporate governance matters.

“We are thrilled to welcome Mark to the team,” said Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna. “His deep expertise across intellectual property strategy and corporate legal matters will be instrumental as we continue to strengthen our governance framework and maximize the value of our portfolio and proprietary Native Complex Platform™. Mark’s leadership will be vital as we scale the capabilities needed to execute on our long-term strategy and deliver new medicines for patients.”

“Septerna represents an extraordinary opportunity to be part of a company that is transforming GPCR drug discovery,” said Mr. Wilson. “I am excited to join this talented team and contribute to the advancement of innovative therapies that have the potential to make a meaningful difference for patients.”

Mr. Wilson joins Septerna from Nektar Therapeutics, where he most recently served as Senior Vice President and Chief Legal Officer. In this role, he served as chief attorney and senior manager for the legal, human resources, and information technology departments, and was a member of the company’s executive committee. During his tenure, Mr. Wilson served as lead attorney for several significant global development and commercialization collaborations, strategic corporate transactions and alternative financings, and he was responsible for the company’s global patent strategy. He joined Nektar in 2002 as Patent Counsel and held roles of increasing responsibility, including Vice President of Intellectual Property and General Counsel. Earlier in his career, Mr. Wilson was an associate at Reed & Associates, a patent law firm in Menlo Park, California, where he represented both start-up and Fortune 500 companies.

Mr. Wilson holds a J.D. from Seton Hall University School of Law and a B.S. in Pharmacy from Rutgers University College of Pharmacy. He is registered to practice before the U.S. Patent and Trademark Office and is a member of the State Bar of California.

About Septerna

Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform™ is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit www.septerna.com.

Investor Contact:
Renee Leck, THRUST
renee@thrustsc.com

Media Contact:
Carly Scaduto, THRUST
carly@thrustsc.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is Mark A. Wilson and what role did Septerna (SEPN) appoint him to on January 8, 2026?

Mark A. Wilson was appointed Chief Legal Officer at Septerna; he has over 25 years of pharma and biotech legal experience.

What experience does Septerna's new CLO Mark A. Wilson bring from his prior employer Nektar Therapeutics?

At Nektar he served as Senior Vice President and Chief Legal Officer, led global patent strategy, major collaborations, strategic transactions and alternative financings.

Does Mark A. Wilson have patent credentials relevant to Septerna's GPCR drug discovery work?

Yes; he is registered to practice before the U.S. Patent and Trademark Office and previously served as Patent Counsel and Vice President of Intellectual Property.

What formal qualifications does Septerna's new CLO hold?

He holds a J.D. from Seton Hall University School of Law and a B.S. in Pharmacy from Rutgers University College of Pharmacy.

Will Mark A. Wilson oversee functions beyond legal at Septerna (SEPN)?

His prior role included oversight of legal, human resources and information technology; the announcement highlights his cross‑functional leadership experience.

Did Septerna specify an effective start date for Mark A. Wilson's appointment?

The company announced the appointment on January 8, 2026; an explicit effective start date was not provided in the announcement.